Henan Lingrui Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001501
CNY
22.07
0.14 (0.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 11.51% and Operating profit at 19.03% over the last 5 years

 
2

Negative results in Mar 25

3

With ROE of 25.60%, it has a attractive valuation with a 4.08 Price to Book Value

4

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 12,506 Million (Large Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

4.08%

stock-summary
Debt Equity

-0.19

stock-summary
Return on Equity

25.60%

stock-summary
Price to Book

4.08

Revenue and Profits:
Net Sales:
1,007 Million
(Quarterly Results - Mar 2025)
Net Profit:
217 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.41%
0%
-3.41%
6 Months
-10.65%
0%
-10.65%
1 Year
-2.17%
0%
-2.17%
2 Years
28.84%
0%
28.84%
3 Years
58.55%
0%
58.55%
4 Years
72.83%
0%
72.83%
5 Years
136.8%
0%
136.8%

Henan Lingrui Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.51%
EBIT Growth (5y)
19.03%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
1.12
Tax Ratio
12.98%
Dividend Payout Ratio
70.26%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
29.45%
ROE (avg)
18.32%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
4.08
EV to EBIT
15.26
EV to EBITDA
13.74
EV to Capital Employed
4.79
EV to Sales
3.25
PEG Ratio
0.72
Dividend Yield
4.08%
ROCE (Latest)
31.41%
ROE (Latest)
25.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 12.38% vs 15.19% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 13.87% vs 31.97% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,006.70",
          "val2": "895.80",
          "chgp": "12.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "235.30",
          "val2": "221.40",
          "chgp": "6.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.10",
          "chgp": "400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.40",
          "val2": "0.70",
          "chgp": "-157.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "216.70",
          "val2": "190.30",
          "chgp": "13.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "233.80%",
          "val2": "225.80%",
          "chgp": "0.80%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.83% vs 10.27% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 27.20% vs 22.09% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,455.50",
          "val2": "3,265.10",
          "chgp": "5.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "798.90",
          "val2": "669.60",
          "chgp": "19.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.60",
          "chgp": "16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "-1.60",
          "chgp": "118.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "722.60",
          "val2": "568.10",
          "chgp": "27.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "209.10%",
          "val2": "179.80%",
          "chgp": "2.93%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
1,006.70
895.80
12.38%
Operating Profit (PBDIT) excl Other Income
235.30
221.40
6.28%
Interest
0.50
0.10
400.00%
Exceptional Items
-0.40
0.70
-157.14%
Consolidate Net Profit
216.70
190.30
13.87%
Operating Profit Margin (Excl OI)
233.80%
225.80%
0.80%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2025 is 12.38% vs 15.19% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 13.87% vs 31.97% in Mar 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
3,455.50
3,265.10
5.83%
Operating Profit (PBDIT) excl Other Income
798.90
669.60
19.31%
Interest
0.70
0.60
16.67%
Exceptional Items
0.30
-1.60
118.75%
Consolidate Net Profit
722.60
568.10
27.20%
Operating Profit Margin (Excl OI)
209.10%
179.80%
2.93%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 5.83% vs 10.27% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 27.20% vs 22.09% in Dec 2023

stock-summaryCompany CV
About Henan Lingrui Pharmaceutical Co., Ltd. stock-summary
stock-summary
Henan Lingrui Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available